IDXX · News · 20260804N
Guidance / Outlook
IDEXX LABORATORIES INC /DE · 2026-08-04 · Importance 57 · Surprise 60 · In source text
Third-party reports said IDEXX raised its full-year 2026 outlook after second-quarter results. The company projected 2026 revenue of $4.70 billion to $4.75 billion and adjusted EPS of $14.69 to $14.94. Reports attributed the improved outlook to continued recurring diagnostics growth, the Technology for Life strategy, and product-cost benefits.
Key facts
- Company provided full-year 2026 EPS guidance of $14.69 to $14.94 and revenue guidance of $4.70 billion to $4.75 billion. source
- Investing.com: IDEXX stock rose nearly 4% in pre-market trading after the company beat estimates and raised guidance. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | unclear | committed | — | Company provided full-year 2026 EPS guidance of $14.69 to $14.94 and revenue guidance of $4.70 billion to $4.75 billion. |
| net_income | unclear | committed | — | Company provided full-year 2026 EPS guidance of $14.69 to $14.94 and revenue guidance of $4.70 billion to $4.75 billion. |